Literature DB >> 31461207

Prognostic value of somatic focal amplifications on chromosome 30 in canine oral melanoma.

Anais Prouteau1, Florian Chocteau2, Clotilde de Brito1, Edouard Cadieu1, Aline Primot1, Nadine Botherel1, Frédérique Degorce3, Laurence Cornevin4, Marie A Lagadic5, Florian Cabillic4, Pauline de Fornel-Thibaud6, Patrick Devauchelle6, Thomas Derrien1, Jerome Abadie2, Catherine André1, Benoît Hédan1.   

Abstract

Canine oral melanoma is the first malignancy of the oral cavity in dogs and is characterized by a local invasiveness and a high metastatic propensity. A better knowledge of genetic alterations is expected to improve management of this tumour. Copy number alterations are known characteristics of mucosal melanomas both in dogs and humans. The goal of this study was to explore the prognostic value of somatic focal amplifications on chromosomes (Canis Familiaris [CFA]) 10 and 30 in canine oral melanoma. The cohort included 73 dogs with oral melanoma confirmed by histology, removed surgically without adjuvant therapy and with a minimal follow-up of 6 months. Epidemiological, clinical and histological data were collected and quantitative-PCR were performed on formalin-fixed paraffin-embedded (FFPE) samples to identify specific focal amplifications. The 73 dogs included in the study had a median survival time of 220 days. Focal amplifications on CFA 10 and 30 were recurrent (49.3% and 50.7% of cases, respectively) and CFA 30 amplification was significantly associated with the amelanotic phenotype (P = .046) and high mitotic index (MI; P = .0039). CFA 30 amplification was also linked to poor prognosis (P = .0005). Other negative prognostic factors included gingiva location (P = .003), lymphadenomegaly (P = .026), tumour ulceration at diagnosis (P = .003), MI superior to 6 mitoses over 10 fields (P = .001) and amelanotic tumour (P = .029). In multivariate analyses using Cox proportional hazards regression, CFA 30 amplification (Hazard ratio [HR] = 2.08; P = .011), tumour location (HR = 2.20; P = .005) and histological pigmentation (HR = 1.87; P = .036) were significantly associated with shorter survival time. Focal amplification of CFA 30 is linked to an aggressive subset and constitutes a new prognostic factor.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  chromosome 30; dog; focal amplification; oral melanoma; prognosis

Mesh:

Year:  2019        PMID: 31461207     DOI: 10.1111/vco.12536

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  5 in total

1.  JARID1-targeted histone H3 demethylase inhibitors exhibit anti-proliferative activity and overcome cisplatin resistance in canine oral melanoma cell lines.

Authors:  Savannah J Tobin; Hong Chang; Michael S Kent; Alexander E Davies
Journal:  Vet Comp Oncol       Date:  2021-03-23       Impact factor: 2.613

2.  Circulating tumor DNA is detectable in canine histiocytic sarcoma, oral malignant melanoma, and multicentric lymphoma.

Authors:  Anaïs Prouteau; Jérôme Alexandre Denis; Pauline De Fornel; Edouard Cadieu; Thomas Derrien; Camille Kergal; Nadine Botherel; Ronan Ulvé; Mélanie Rault; Amira Bouzidi; Romain François; Laetitia Dorso; Alexandra Lespagnol; Patrick Devauchelle; Jérôme Abadie; Catherine André; Benoît Hédan
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

3.  KIT Somatic Mutations and Immunohistochemical Expression in Canine Oral Melanoma.

Authors:  Ginevra Brocca; Beatrice Poncina; Alessandro Sammarco; Laura Cavicchioli; Massimo Castagnaro
Journal:  Animals (Basel)       Date:  2020-12-10       Impact factor: 2.752

Review 4.  Diagnosis and Prognosis of Canine Melanocytic Neoplasms.

Authors:  Rebecca C Smedley; Kimberley Sebastian; Matti Kiupel
Journal:  Vet Sci       Date:  2022-04-06

5.  Canine Oral Melanoma Genomic and Transcriptomic Study Defines Two Molecular Subgroups with Different Therapeutical Targets.

Authors:  Anais Prouteau; Stephanie Mottier; Aline Primot; Edouard Cadieu; Laura Bachelot; Nadine Botherel; Florian Cabillic; Armel Houel; Laurence Cornevin; Camille Kergal; Sébastien Corre; Jérôme Abadie; Christophe Hitte; David Gilot; Kerstin Lindblad-Toh; Catherine André; Thomas Derrien; Benoit Hedan
Journal:  Cancers (Basel)       Date:  2022-01-06       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.